Our biotech ETF buy has tripled the gains of the Dow since we first recommended it three-and-a-half years ago.
We expect those market-beating gains to continue because of these 4 catalysts.
by Ashley Moore
Our biotech ETF buy has tripled the gains of the Dow since we first recommended it three-and-a-half years ago.
We expect those market-beating gains to continue because of these 4 catalysts.
Not to mention, one of the stocks in the fund is set to gain as much as 178% this year...
Start the conversation